X4 Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Browse to the bottom of this page for potential risks for X4 Pharmaceuticals Inc based on industry, location and size. The ESG score for X4 Pharmaceuticals Inc indicates its reporting of the UN Sustainable Development Goals. Full Sustainability analysis of X4 Pharmaceuticals Inc are accessed by logging in.
X4 Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.7, social score of 1.6 and governance score of 6.0.
3.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1186 | Simply Better Brands Corp | 3.5 | Medium |
| 1186 | Yunnan Baiyao Group Co Ltd | 3.5 | Medium |
| 1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
| 1234 | Cassava Sciences Inc | 3.4 | Medium |
| 1234 | Brickell Biotech Inc | 3.4 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does X4 Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes X4 Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid X4 Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas X4 Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs X4 Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes X4 Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes X4 Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for X4 Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.